For nearly 30 years, Luitpold Animal Health, a division of Luitpold Pharmaceuticals, Inc., has been committed to advancing animal health with proven FDA-approved products like Adequan. The company’s portfolio is anchored by the only FDA-approved equine polysulfated glycosaminoglycan for the intramuscular treatment of non-infectious degenerative joint disease of the carpal and hock joints, which has been relied on for nearly three decades by equine practitioners. As the manufacturer of Adequan Canine, the company recently returned marketing and distribution of the product to its portfolio, reflecting its position as a leader in joint health care for horses and dogs. Luitpold Pharmaceuticals, Inc., a Daiichi Sankyo Group Company, manufactures and distributes more than 100 human pharmaceutical products and devices, as well as innovative products for acute pain control and veterinary medicine use. The company continues to invest in its animal health portfolio as a strategic priority.